| Literature DB >> 24803936 |
Naveen Gupta1, Renu Saigal2, Laxmikant Goyal1, Abhishek Agrawal1, Rajat Bhargava1, Arun Agrawal1.
Abstract
Aim. Increased cardiovascular morbidity and mortality have been observed in ankylosing spondylitis because of accelerated atherosclerosis. We measured carotid intima media thickness (CIMT) as a surrogate marker of atherosclerosis in this study. Methods. In this study 37 cases of AS and the same number of matched individuals were recruited. CIMT measurements were done using B-mode ultrasound. Disease activity was assessed using Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), and Bath ankylosing spondylitis metrological index (BASMI) scores and C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels. Results. Mean age of the study groups was 29.43 ± 9.00 years. Average disease duration was 65.62 ± 54.92 months. Twenty-eight (75.68%) of cases were HLA B-27 positive. A significantly increased CIMT was observed in cases as compared to control group (0.62 ± 0.12 versus 0.54 ± 0.04; P < 0.001). CIMT in the cases group positively correlated with age (r = 0.357; P < 0.05), duration of disease (r = 0.549; P < 0.01), and BASMI (r = 0.337; P < 0.05) and negatively correlated with ESR (r = -0.295; P < 0.05). Conclusions. Patients of AS had a higher CIMT than those of the control group. CIMT correlated with disease chronicity.Entities:
Year: 2014 PMID: 24803936 PMCID: PMC3997910 DOI: 10.1155/2014/839135
Source DB: PubMed Journal: Int J Rheumatol ISSN: 1687-9260
Characteristics of study subjects.
| Cases of AS (37) | Healthy controls (37) |
| |
|---|---|---|---|
| Age (range) (years) | 29.43 ± 9.0 (17–50) | 29.43 ± 9.0 (17–50) | >0.05 |
| Age at onset (years) | 24.01 ± 8.36 | — | |
| Disease duration (months) | 65.62 ± 54.92 | — | |
| BASDAI | 4.11 ± 1.99 | — | |
| BASFI | 4.13 ± 2.09 | — | |
| BASMI | 3.14 ± 2.14 | — | |
| ESR (mm/hr) | 45.19 ± 26.04 | — | |
| CRP (mg/dL) | 7.36 ± 3.78 | — | |
| HLA-B27 (% of cases) | 75.68 | ||
| CIMT (mm) | 0.62 ± 0.12 | 0.54 ± 0.04 | <0.001 |
| TG (mg/dL) | 93.65 ± 36.18 | 108.62 ± 41.52 | >0.05 |
| HDL-c (mg/dL) | 47.92 ± 6.44 | 44.92 ± 3.86 | >0.05 |
| LDL-c (mg/dL) | 80.96 ± 21.66 | 107.36 ± 25.84 | <0.001 |
Correlation of CIMT with markers of disease severity and chronicity.
| Correlation coefficient ( |
| |
|---|---|---|
| CIMT and age | +0.357 |
|
| CIMT and disease duration | +0.549 |
|
| CIMT and age at onset | +0.086 | >0.05 |
| CIMT and BASDAI | −0.160 | >0.05 |
| CIMT and BASFI | +0.059 | >0.05 |
| CIMT and TTW | +0.098 | >0.05 |
| CIMT and lateral flexion | −0.344 |
|
| CIMT and IMD | −0.268 |
|
| CIMT and CR | −0.296 |
|
| CIMT and lumbar flexion | −0.313 |
|
| CIMT and BASMI | +0.337 |
|
| CIMT and ESR | −0.295 |
|
| CIMT and CRP | −0.133 | >0.05 |
| CIMT and TG | −0.024 | >0.05 |
| CIMT and HDLc | +0.106 | >0.05 |
| CIMT and LDLc | +0.189 | >0.05 |
| CIMT and HLA B-27 positivity | — | >0.05 |